CROI 2024: Global Epidemiology and Prevention of HIV and Other Sexually Transmitted Diseases (Q30296)

abstract

At the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), investigators presented updates on the global HIV epidemic, focusing on ongoing disparities by race/ethnicity in the US, the ongoing concentration of new infections among men who have sex with men (MSM) and transgender women in the Americas, and a shift to a greater total number of infections now in low versus high [...] (English)

1

1 reference

HIV testing, the gateway to prevention and to treatment, has not fully rebounded from the substantial declines seen during the early COVID-19 pandemic in some settings, although innovative strategies including home testing and opt-out testing in clinical settings appear to be reaching populations in need of testing. (English)

2

1 reference

Several investigators reported on the efficacy and effectiveness of doxycycline used as postexposure prophylaxis (doxy-PEP) to prevent bacterial sexual transmitted infections in MSM and transgender women in clinical trials and clinic settings; citywide rates of chlamydia and syphilis have decreased in San Francisco after the rollout of the first doxy-PEP guidelines in the US. (English)

3

1 reference

Lack of doxy-PEP efficacy in cisgender women in Kenya appears due to low adherence in that trial. (English)

4

1 reference

Rollout and persistence on oral HIV preexposure prophylaxis (PrEP) are associated with reduced seroincidence on a population and individual level. (English)

5

1 reference

The rollout of long-acting injectable cabotegravir (CAB-LA) PrEP is proceeding slowly in the US. (English)

6

1 reference

New, longer-acting oral and injectable agents are in development, with preclinical and early clinical trial data presented at CROI. (English)

7

1 reference

Oral PrEP uptake among populations in sub-Saharan Africa remains low in most settings, suggesting the need for more options and more support; point-of-care tenofovir testing appear acceptable in various populations and may improve adherence and identify PrEP users needing more support. (English)

8

1 reference

Choice of PrEP or PEP including CAB-LA combined with clinical support substantially increased biomedical prevention coverage in East Africa. (English)

9

1 reference